Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Trial Profile

Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Apr 2010 Additional trial investigator [Rose A] identified as reported by United Kingdom Clinical Research Network record.
    • 29 Apr 2010 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top